Announcements Trials
Browse Landscape

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 8Lymphoid 7Gastrointestinal 6Other hematologic neoplasm 5CNS 5Breast 5Gynecologic 4Thoracic 3Sarcoma 2Plasma cell 2Myeloid 2Endocrine 2Dermatologic 2Other solid neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 31Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7Capecitabine 7X-Rays 6Etoposide 6surufatinib 5olaparib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Positron-Emission Tomography × Endocrine × 1 year × Clear all
NCT04069299 2026-03-31

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

H. Lee Moffitt Cancer Center and Research Institute

Completed
30 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Active not recruiting
11 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡